



November 17, 2020

To whom it may concern,

Company: Japan Lifeline Co., Ltd.  
Representative: Keisuke Suzuki, President and CEO  
(Code: 7575 TSE 1st Section)  
Contact person: Kenji Yamada, Senior Vice President,  
Corporate Administration Headquarters  
(TEL. +81-3-6711-5200)

### **Notice Regarding the Execution of the Contract for Sales of Japan Lifeline's EP Catheters in Europe**

Japan Lifeline Co., Ltd. ("the Company") is pleased to inform that it has entered into a sales contract with Baylis Medical Company, Inc. ("Baylis Medical") for sales of EP (electrophysiological) catheters manufactured and sold by the Company in the European market.

Baylis Medical is a developer and manufacturer of the radio frequency atrial septal puncture needle, "NRG® Transseptal Needle", which the Company exclusively sells in Japan. The "NRG® Transseptal Needle" is a one-of-a-kind device and is widely used as an indispensable medical tool to enable the delivery of various cardiac therapies. In addition, Baylis Medical has introduced the EP catheters manufactured by the Company in North America since last year, and the two companies have strengthened their cooperative relationship.

Among the Company's extensive product lineup of EP catheters, the products that will be introduced to the European market this time will be the extremely small-diameter 2Fr EP catheter and 6Fr EP catheter with lumen, of which there are very few similar products on the market. These products are specialized for placement in the coronary sinus. By using both products in combination, it is possible to access the distal part of the coronary sinus, which is difficult with a standard EP catheter, and contributes to an accurate diagnosis and treatment of arrhythmias. Furthermore, the 2Fr EP catheter is expected to be a catheter that can acquire potential information within the left atrial oblique vein (Marshall vein), which has been attracting much attention in recent years in relation to persistent atrial fibrillation.

Since the products currently to be introduced to the European market will be limited to the above two products, the Company expects that the contribution to the business performance will be limited, but the Company is eager to develop products that can make use of its technological capabilities for Europe as well as North America. The Company aims to tackle the overseas expansion by accumulating a track record of the overseas sales of its in-house products.

#### **About Baylis Medical**

Baylis Medical Company, Inc. is a leading company in the development, manufacturing and sales of medical devices within the cardiovascular field. Headquartered in Canada and with offices around the world, the company has been improving the lives of people around the world for over 30 years. "NRG" is a trademark or registered trademark of Baylis Medical in the USA and/or other countries. For details, please refer to the following website: <https://www.baylismedical.com/>